A range of factors contributing to the acquired phenotype of DR resistance in breast cancer have been proposed, including the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway [36] and the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) [37]. This evidence concerns the gene WNK2 and breast cancer.